Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development for progressive familial intrahepatic cholestasis and Alagille syndrome. Mirum Pharmaceuticals Inc. is based in Foster City, United States.
Info & Links
CEO
Christopher Peetz
Headquarters
989 EAST HILLSDALE BOULEVARD, SUITE 300 FOSTER CITY, CA 94404, UNITED STATES
Mirum Pharmaceuticals, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
5.65B
Enterprise Value
5.67B
Enterprise Value/EBITDA(ttm)
1.47K
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
11.34
Price to Book(mrq)
16.00
Price to Cash(ytd)
1.92K
Profitability
Gross Margin(ttm)
80.72%
Operating Margin(ttm)
-4.48%
Profit Margin(ttm)
-4.85%
Return on Equity(ttm)
-8.53%
Return on Invested Capital(ttm)
-4.18%
Return on Assets(ttm)
-3.07%
Income Statement
Revenue(ttm)
521.31M
Revenue Per Share(ttm)
8.64
Gross Profit(ttm)
421.07M
EBITDA(ttm)3
3.85M
Net Income Available to Common(ttm)
-23.36M
Diluted EPS(ttm)
-0.48
Share Statistics
Beta (5Y Monthly)
0.51
52-Week Change
129.36%
S&P 500 52-Week Change
27.10%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
60.34M
Dividend Yield
0.00%
Float4
51.68M
% Held by Insiders
14.36%
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
383.33M
Total Cash Per Share(mrq)
6.35
Total Debt(mrq)
309.80M
Total Debt/Equity(mrq)
98.45%
Current Ratio(mrq)
2.67%
Quick Ratio(mrq)
2.55%
Book Value Per Share(mrq)
6.06
Cash Flow
Operating Cash Flow Per Share(ytd)
1.11
Free Cash Flow(ytd)
54.87M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.